SUSRF (Surgical Science Sweden AB) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is Surgical Science Sweden AB LT-Debt-to-Total-Asset?

Surgical Science Sweden AB SUSRF -2.20% 82 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates SUSRF with a GF Score™ of 82/100 and a GF Value™ of $19.33 (Significantly Undervalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Surgical Science Sweden AB's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Surgical Science Sweden AB's long-term debt to total assets ratio stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00).

Surgical Science Sweden AB (OTCPK:SUSRF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Surgical Science Sweden AB LT-Debt-to-Total-Asset Related Terms

Surgical Science Sweden AB LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Surgical Science Sweden AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surgical Science Sweden AB LT-Debt-to-Total-Asset Chart

Surgical Science Sweden AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.01

Surgical Science Sweden AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.00	0.00	0.01	0.00

82GF Score

Surgical Science Sweden AB SUSRF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Surgical Science Sweden AB LT-Debt-to-Total-Asset Calculation

Surgical Science Sweden AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	6.068	/	504.801
	=	0.01

Surgical Science Sweden AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0	/	515.631
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

Surgical Science Sweden AB (SUSRF) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Surgical Science Sweden AB and its competitors.

Is Surgical Science Sweden AB's LT-Debt-to-Total-Asset too high?

Surgical Science Sweden AB's current LT-Debt-to-Total-Asset is 0.00. Overall, Surgical Science Sweden AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Surgical Science Sweden AB's LT-Debt-to-Total-Asset compare to VEEV and BTSG?

Surgical Science Sweden AB's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Healthcare Providers & Services company?

A good LT-Debt-to-Total-Asset depends on the Healthcare Providers & Services industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Surgical Science Sweden AB and its competitors. Surgical Science Sweden AB's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Surgical Science Sweden AB stock overvalued right now?

Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $19.33, compared to a current price of $4.00 — trading 79.3% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?

Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued. The current stock price of $4.00 is trading 79.3% below its estimated GF Value™ of $19.33. GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.

Key valuation signals for SUSRF:

LT-Debt-to-Total-Asset: 0.00
GF Value™: $19.33 vs. price of $4.00 (79.3% below fair value)
GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Surgical Science Sweden AB Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies OSTO:CARA NGM:H100 OSTO:PTRK XSAT:SYNT XSAT:KONT OSTO:AINO OSTO:RAY B VEEV ASX:PME BTSG TEM HQY TSE:2413 HNGE TXG DOCS WAY HKSE:02228 PRVA HTFL

Other Exchanges SUS:Sweden 4P41:Germany

Address Drakegatan 7A, Gothenburg, SWE, SE-412 50

Website https://www.surgicalscience.com

Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.

82GF Score

Get the complete analysis for SUSRF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.00

Price

$19.33

GF Value

View SUSRF Analysis

See LT-Debt-to-Total-Asset data for all stocks →